Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;12(7):e061725.
doi: 10.1136/bmjopen-2022-061725.

Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial

Ronald Kiguba  1 , Norah Mwebaza  2 , Ronald Ssenyonga  3 , Helen Byomire Ndagije  4 , Victoria Nambasa  4 , Cordelia Katureebe  5 , Kenneth Katumba  6 , Phil Tregunno  7 , Kendal Harrison  7 , Charles Karamagi  8 , Kathryn A Scott  9 , Munir Pirmohamed  9
Affiliations

Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial

Ronald Kiguba et al. BMJ Open. .

Erratum in

Abstract

Introduction: Combination antiretroviral therapy (cART) has massively reduced HIV mortality. However, long-term cART increases the risk of adverse drug reactions (ADRs), which can lead to higher morbidity, mortality and healthcare costs for people living with HIV (PLHIV).Pharmacovigilance-monitoring the effects of medicines-is essential for understanding real-world drug safety. In Uganda, pharmacovigilance systems have only recently been developed, and rates of ADR reporting for cART are very low. Thus, the safety profile of medicines currently used to treat HIV and tuberculosis in our population is poorly understood.The Med Safety mobile application has been developed through the European Union's Innovative Medicines Initiative WEB-Recognising Adverse Drug Reactions project to promote digital pharmacovigilance. This mobile application has been approved for ADR-reporting by Uganda's National Drug Authority. However, the barriers and facilitators to Med Safety uptake, and its effectiveness in improving pharmacovigilance, are as yet unknown.

Methods and analysis: A pragmatic cluster-randomised controlled trial will be implemented over 30 months at 191 intervention and 191 comparison cART sites to evaluate Med Safety. Using a randomisation sequence generated by the sealed envelope software, we shall randomly assign the 382 prescreened cART sites to the intervention and comparison arms. Each cART site is a cluster that consists of healthcare professionals and PLHIV receiving dolutegravir-based cART and/or isoniazid preventive therapy. Healthcare professionals enrolled in the intervention arm will be trained in the use of mobile-based, paper-based and web-based reporting, while those in the comparison arm will be trained in paper-based and web-based reporting only.

Ethics and dissemination: Ethical approval was given by the School of Biomedical Sciences Research and Ethics Committee at Makerere University (SBS-REC-720), and administrative clearance was obtained from Uganda National Council for Science and Technology (HS1366ES). Study results will be shared with healthcare professionals, policymakers, the public and academia.

Trial registration number: PACTR202009822379650.

Keywords: Adverse events; CLINICAL PHARMACOLOGY; EPIDEMIOLOGY; Epidemiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Med Safety mobile app. MHRA, medicines and healthcare products regulatory agency; NDA, national drug authority.
Figure 2
Figure 2
Flow diagram for cluster-randomised trial at full rollout. ADR, adverse drug reaction.
See this image and copyright information in PMC

References

    1. Grant AD, Mngadi KT, van Halsema CL, et al. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 2010;24 Suppl (5):S29–36. 10.1097/01.aids.0000391019.10661.66 - DOI - PubMed
    1. Kiguba R, Karamagi C, Waako P, et al. Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants. BMJ Open 2014;4:e005869. 10.1136/bmjopen-2014-005869 - DOI - PMC - PubMed
    1. Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS 2018;32:903–12. 10.1097/QAD.0000000000001781 - DOI - PubMed
    1. Pierce CE, de Vries ST, Bodin-Parssinen S, et al. Recommendations on the use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from ImI WEB-RADR. Drug Saf 2019;42:477–89. 10.1007/s40264-019-00813-6 - DOI - PMC - PubMed
    1. Bahk CY, Goshgarian M, Donahue K, et al. Increasing patient engagement in pharmacovigilance through online community outreach and mobile reporting applications: an analysis of adverse event reporting for the Essure device in the US. Pharmaceut Med 2015;29:331–40. 10.1007/s40290-015-0106-6 - DOI - PMC - PubMed

Publication types

MeSH terms